[en] In micro-CT imaging, many approaches have already been performed to correct artifacts due to degrading phenomena such as beam hardening and scattering. The aim of our study is to develop a reliable analytical simulation toolkit taking into account the polychromaticity of the source spectrum and the detector defaults. This toolkit will then be used to validate and optimize correction methods in order to reduce artifacts in image reconstruction. (orig.)

[en] Introduction: Since 1991 until now, many radiosyntheses of ["1"8F]FLT have been published. Most of them suffer from side reactions and/or difficult purification related to the large amount of precursor necessary for the labeling step. A fully automated synthesis using only commercial and unmodified materials with a reduced amount of precursor would be desirable. Methods: We first explored the possibility to elute efficiently ["1"8F]fluorine from commercial and unmodified cartridges with various amount of base. Based on these results, 10 mg and 5 mg of precursors were used for the fluorination step. The best conditions were transposed in an automated process for a one pot two steps synthesis of labeled FLT. Results: Using commercial and non-treated carbonate form of QMA cartridges, we were able to elute quantitatively the ["1"8F]fluorine with a very low amount of base (0.59 mg) and, with only 5 mg of precursor, to perform an efficient fluorination reaction with up to 94% incorporation of ["1"8F]fluorine. The synthesis was fully automated and radiochemical yields of 54% (decay corrected) were obtained within a synthesis time of 52 minutes. Conclusion: We demonstrate that a fully automated and efficient radiosynthesis of ["1"8F]FLT is feasible with only 5 mg of precursor. Compare to the present state of the art, our method provides high yields of pure ["1"8F]FLT and is broadly adaptable to other synthesis automates.

[en] This document contains Power Point presentations and texts of contributions to a meeting held in video-conference. After an overview of the organization of the different IN2P3 platforms, of the IN2P3 labeled irradiation platforms, the contributions propose activity reports, presentations of works and researches, indications of publications related to the different platforms: Alto (a facility comprising two accelerators), Aifira (for Interdisciplinary Applications of ion beams in the Aquitaine region), Andromede (a new instrument for the analysis by mass spectrometry of nano-fields and nano-objects presents on a surface), Cyrce (a cyclotron), Genesis (group of studies and nano-analyses of irradiation effects, an instrumental platform for the characterization of materials at a very fine scale), Scalp (Synthesis and Characterization using Accelerators for Pluridisciplinary research in materials, astrophysics, geology and nuclear physics), 'EmirA' (French national network of accelerators for irradiation and analysis of molecules and materials).

[en] Platelets play a major role in thrombo-embolic diseases, notably by forming a thrombus that can ultimately occlude a vessel. This may provoke ischemic pathologies such as myocardial infarction, stroke or peripheral artery diseases, which represent the major causes of death worldwide. The aim of this study was to evaluate the specificity of radiolabeled Rat-Anti-Mouse antibody (RAM.1).

[en] Herein we have evaluated the uptake of O-(2-¹⁸F-fluoroethyl)-l-tyrosine (¹⁸F-FET) in insulinoma in comparison with those of 6-¹⁸F-fluoro-3,4-dihydroxy-l-phenylalanine (¹⁸F-FDOPA) providing first data from both murine xenograft model and one patient with proved endogenous hyperinsulinemic hypoglycemia.

[en] Four main topics were approached during this seminar on vectorized internal radiotherapy (VIR): clinical challenges, vectors and radionuclides, dosimetry and radiobiology. Content of this book of abstracts: 1 - Present (and future) clinical challenges of VIR: Invited presentations; General presentation of present day clinical challenges of VIR and future perspectives; VIR news in solid tumors including early stages; Clinical impact of personalized dosimetry for SIRT of liver cancers; Theranostics and role in VIR; Personalised dosimetry for thyroid cancers with metastases: ancillary study of the MERAIODE clinical assay; Dosimetric workflow adapted to the number of available SPECT/CT acquisitions for ¹⁷⁷Lu-DOTATATE treatments; International clinical dosimetry intercomparison - Conclusion and perspectives; MEDIRAD clinical dosimetry study: results and conclusions; 2 - What radionuclides and what vectors/ligands? Radionuclides and their production; Present day vectors of radionuclides therapy; Metallic radiopharmaceutical products: how to chose the chelate? Radio-pharmacy implementation, good fabrication practice; High separation factor between ¹⁶⁵Er and Ho for an Auger therapy application; Theranostic developments at the Cerimed research centre; BePAT project: BeaQuant, a digital autoradiograph for radionuclides production for nuclear medicine applications; ⁶⁷Cu production with CYRCe; Microfluidics automatized production of radiopharmaceuticals for theranostics; 3 - Dosimetry: Dosimetry in Molecular Radiotherapy: Trials, Tribulations and Transcendence; Clinical dosimetry: Nantes' experience; Clinical dosimetry: Montpellier's experience; Preclinical dosimetry of VIR; Development of a portable gamma camera for the control and optimization of the delivered dose in internal radiotherapy; Pre-treatment dosimetry in SIRT: Is it possible to optimize SPECT/CT reconstructions and calculation methods for accurate dosimetry? Dosimetric impact of respiration movements compensation in radioembolization; Monte Carlo track structure simulations and the biophysical model NanOx in targeted radionuclide therapy; Comparison of absorbed dose calculation algorithms in PLANET^R Dose and Open-Dose3D; 4 - Radiobiology: External radiotherapy radiobiology; Radiobiology of molecular radionuclide therapy: contribution of targeted and non-targeted effects; Clinical Radiobiology; Immunological aspects of Targeted Alpha Therapy response; Evaluation of uncertainties in pre-clinical cellular dosimetry of ¹¹¹In-labeled radiopharmaceutical; Impact of intracellular radionuclide distribution in Targeted Alpha Therapy: a Monte Carlo biophysical study in 3D multicellular model; Targeting cancer cells nucleus with indium-111 labelled immuno-conjugates in a VIR context; Response of cancer-associated fibroblasts (CAF) to Targeted Radionuclide Therapy of pancreatic cancer microenvironment